---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125920"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:00:59.988469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer

## Summary
- Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.
- Cash and securities $202.8M as of Sep 30, 2024; expected to fund into H2 2026.
- ACR-368 Phase 2b endometrial cancer: confirmed ORR 62.5% in OncoSignature-positive patients (p=0.009).
- ACR-2316 Phase 1 dose-escalation cohort fully enrolled; initial data expected H2 2025.
- Company sees endometrial cancer as first potential approval opportunity for ACR-368.

## SEC filing metadata
- accession: 0000950170-24-125920
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/0000950170-24-125920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/acrv-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125920
- JSON: https://secwatch.observer/filing/0000950170-24-125920.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.